anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND Cervical spondylosis (CS) is a degenerative disease of the cervical spine characterized by persistent neck pain. Cervical facet joint mobilization (CM) and the osteopathic muscle energy technique (MET) are effective manual procedures for the treatment of neck pain. In this study, we compared the efficacy of the MET and CM techniques on pain, disability, and proprioception in 76 patients with CS. MATERIAL AND METHODS A total of 96 participants with a diagnosis of CS were randomized into an electro-thermal therapy (ET) group (control group, n=32), ET+MET group (experiment I, n=32), and ET+CM group (experiment II, n=32). All patients received 3 treatment sessions per week for 4 consecutive weeks. Pain intensity, functional disability and cervical position sense were measured using the visual analog scale (VAS), Copenhagen Neck Functional Disability Scale (CNFDS), and cervical range of motion (CROM) device. RESULTS The study was completed by 76 participants. VAS and CNFDS scores decreased significantly after treatment in all 3 groups (P<0.001); however, there was no significant difference between the groups (P>0.05). Between-group analysis showed a significant difference in extension joint position error in favor of MET (P<0.001), while there was no significant difference between the groups in other movement directions (P>0.05). CONCLUSIONS MET and CM have similar effects on improving pain and disability in individuals with CS and chronic neck pain. However, the results of this study show that MET combined with ET is a more effective method for improving cervical position sense.
Provided is a polymersome composition that has skin disorder remedying effects, that is safe, that provides a pleasant feel upon use and a fresh feel without any stickiness, and that has excellent base-agent stability. The disclosed polymersome contains, as a membrane component, a block-type alkylene oxide derivative represented by the following formula (I): R1O-[(EO)l(AO)m(EO)n]-R2. (In the formula, AO represents an oxyalkylene group having 3 or 4 carbons; EO represents an oxyethylene group; m represents an average addition mole number of the oxyalkylene group and satisfies 1=m=70; and 1+n represents an average addition mole number of the oxyethylene group and satisfies 1=1+n=70. The percentage of the oxyethylene group to the sum of the oxyalkylene group having 3 or 4 carbons and the oxyethylene group is 20% to 80% by mass. The oxyalkylene group having 3 or 4 carbons and the oxyethylene group are added blockwise. R1 and R2 each represent a hydrocarbon group having 1 to 4 carbons, which may be the same or different from each other.)
In accordance with a preferred embodiment of the invention, posting a health message to the community is simple for health sponsors since all they need is a phone—no Internet access is required. Since health messages can be posted quickly, the system can support a community's need for timely information even about local health emergencies. For users, audio messages, that have a simple linear organization from start-to-finish, are preferable to printed messages. Even users with slow dial-up modem access to the Internet can easily listen to the audio health messages. While the Web is a worldwide resource, embodiments of the invention serve a ‘community’ of users with like interest by providing health information useful to the community. Since dissemination of timely health information is beneficial to the community, use of embodiments of the invention in the form of a Community Health Support system by Health Sponsors and community members reinforces the value of the system to the community.
The aim of this study was to investigate the effects of neurodynamic mobilization (NM) technique on muscle damage and inflammation biomarkers, and pain, pressure pain threshold, and functional status in delayed onset muscle soreness (DOMS). In the study, 34 healthy sedentary male volunteers were randomly divided into two groups as NM (n = 17) and SHAM-NM (n = 17). After the initial evaluation of the individuals, femoral nerve NM and placebo NM techniques were administered three sets a day with ten repetitions for three days a week for three weeks. Three days after the end of the applications, the second evaluations were made and the DOMS creation protocol for the quadriceps femoris (QF) muscle was initiated. In order to trigger DOMS in individuals, 30 sets and 10 repetitions of eccentric knee extension (35°-95° flexion angles, 30°/sec speed) were performed on the dominant lower extremity with an isokinetic dynamometer. Baseline evaluations were repeated immediately after the DOMS protocol, and at hours 24, 48, and 72. During evaluations, muscle damage (serum creatine kinase (CK), lactate dehydrogenase (LDH), and inflammation (interleukin-6 (IL-6), tumor necrosis factor-alpha) biomarkers, pain (activity), pressure pain threshold, and performance (one-leg jump, vertical jump) parameters were measured.
Individual Virtual Reality will be delivered using virtual reality glasses for 30-45 minutes during dialysis sessions. Those randomized to this arm will watch a movie or program alone through the glasses.
PROBLEM TO BE SOLVED: To obtain glycolipid efficiently without being accompanied by a colorant as least as possible by extracting grain with a hydrophilic org. solvent and extracting the resultant extract with a nonhydrophilic org. solvent. SOLUTION: Grain is extracted with 1-10 times as much hydrophilic org. solvent selected from among ethanol, methanol, and acetonitrile under boiling reflux for 3-5 hr to give an extract, which is then extracted with a nonhydrophilic org. solvent selected from among hexane, chloroform, ether, and ethyl acetate. Thus obtd. extract is concentrated to give glycolipid. This glycolipid in an amt. of 0.1-50 wt.% is added e.g. to wheat germ oil to give a material for cosmetics. This material is added to a cosmetic in such an amt. that the glycolid content in the cosmetic is 0.1-20 wt.%, pref. 0.1-10 wt.%. The glycolipid is added also to a food in an amt. of 0.01-30 wt.%, pref. 0.1-15 wt.%, of the food.
BACKGROUND: Mitochondria play essential roles in tumorigenesis; however, little is known about the contribution of mitochondrial DNA (mtDNA) to esophageal squamous cell carcinoma (ESCC). Whole-genome sequencing (WGS) is by far the most efficient technology to fully characterize the molecular features of mtDNA; however, due to the high redundancy and heterogeneity of mtDNA in regular WGS data, methods for mtDNA analysis are far from satisfactory.
METHODS: Here, we developed a likelihood-based method dMTLV to identify low-heteroplasmic mtDNA variants. In addition, we described fNUMT, which can simultaneously detect non-reference nuclear sequences of mitochondrial origin (non-ref NUMTs) and their derived artifacts. Using these new methods, we explored the contribution of mtDNA to ESCC utilizing the multi-omics data of 663 paired tumor-normal samples.
RESULTS: dMTLV outperformed the existing methods in sensitivity without sacrificing specificity. The verification using Nanopore long-read sequencing data showed that fNUMT has superior specificity and more accurate breakpoint identification than the current methods. Leveraging the new method, we identified a significant association between the ESCC overall survival and the ratio of mtDNA copy number of paired tumor-normal samples, which could be potentially explained by the differential expression of genes enriched in pathways related to metabolism, DNA damage repair, and cell cycle checkpoint. Additionally, we observed that the expression of CBWD1 was downregulated by the non-ref NUMTs inserted into its intron region, which might provide precursor conditions for the tumor cells to adapt to a hypoxic environment. Moreover, we identified a strong positive relationship between the number of mtDNA truncating mutations and the contribution of signatures linked to tumorigenesis and treatment response.
CONCLUSIONS: Our new frameworks promote the characterization of mtDNA features, which enables the elucidation of the landscapes and roles of mtDNA in ESCC essential for extending the current understanding of ESCC etiology. dMTLV and fNUMT are freely available from https://github.com/sunnyzxh/dMTLV and https://github.com/sunnyzxh/fNUMT , respectively.
PURPOSE: Endovascular reconstruction has emerged as a viable alternative for carotid artery dissections (CADs) that are unresponsive to antithrombotic therapy. However, high cervical and long-segment CADs pose challenges during endovascular treatment due to their distal location and tortuous anatomy. We presented our experiences using endovascular reconstruction with the Leo plus stent for this type of CAD.
METHODS: We conducted a retrospective review of patients with high cervical and long-segment CADs treated using the Leo plus stent. We analyzed patient demographics, clinical presentations, procedural features, complications, and follow-up outcomes.
RESULTS: A total of 17 patients (mean age, 48.1 years) with 17 CADs were identified. Seven of these dissections were accompanied by pseudoaneurysm. The mean length of the dissection was 5.7 cm, and the mean degree of stenosis was 92.3%. A single Leo plus stent was deployed in 15 patients, while another Wallstent carotid stent was used in 2 cases. All stents were successfully positioned in their intended sites. The average degree of residual stenosis was 22.2%. There were no perioperative complications. With a median follow-up duration of 29 months, no ischemic stroke events occurred. All but one Leo plus stent remained patent during follow-up, and all 7 pseudoaneurysms had disappeared at the last radiological assessment.
CONCLUSION: Our experience in treating high cervical and long-segment CADs with the Leo plus stent demonstrates that this approach is practical, safe, and effective, as evidenced by long-term observations. The Leo Plus stent appears to be a suitable option for managing this type of CAD.
Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
Malnutrition is an important risk factor for multiple organ dysfunction syndrome in the elderly (MODSE) and seriously affects the occurrence, progression and prognosis of MODSE. Shenling Baizhu Power (SBP), a classic formula from traditional Chinese medicine (TCM), when integrated with enteral nutrition, has been proven to be an effective clinical strategy for treating the patients of MODSE with malnutrition. This study aimed to investigate the metabolic changes during disease occurrence and SBP treatment, and to discover potential metabolic biomarkers for the diagnosis and efficacy evaluation. An untargeted metabolomics strategy based on UHPLC-Q-Orbitrap-HRMS was performed to reveal the differential serum metabolites between MODSE patients with malnutrition (n=59) and healthy controls (n=33), and those between patients treated with enteral nutrition (n=31) and SBP combined with enteral nutrition (n=28). Significantly different metabolites were identified and mapped onto the network of metabolic pathways to explore the metabolic disorders caused by the disease and the metabolic regulatory mechanism of SBP. Additionally, the area under the curve (AUC) of the potential biomarkers was investigated for predicting the disease and the efficacy of SBP. Sixty differential metabolites were identified between the disease and control groups, which were mainly related to amino acid metabolism, energy metabolism and carbohydrate metabolism. In the same way, 50 differential metabolites associated with SBP treatment were identified, which improved metabolic abnormalities in vivo mainly by regulating the above-mentioned metabolic pathways. Finally, 13 differential metabolites in common were selected as the potential biomarkers and the AUC value of each biomarker was within the range of 0.8-1.0, indicating that these biomarkers had high prediction accuracy for the diagnosis and efficacy evaluation of MODSE with malnutrition. This study demonstrates that serum metabolomics approaches based on the UHPLC-Q-Orbitrap-HRMS platform can be applied as a tool to reveal the metabolic changes induced by MODSE with malnutrition and SBP can play an important role in the clinical application.
* ENVARSUS XR (tacrolimus extended-release tablets) is not interchangeable or substitutable with tacrolimus extended-release capsules, tacrolimus capsules, and tacrolimus for oral suspension. Under or overexposure to tacrolimus may result in graft rejection or other serious adverse reactions [see Warnings and Precautions (5.3)]. ENVARSUS XR should not be used without the supervision of a physician with experience in immunosuppressive therapy.
  * ENVARSUS XR should be taken on an empty stomach consistently at the same time of the day, preferably in the morning to ensure consistent and maximum possible drug exposure, at least 1 hour before a meal or at least 2 hours after a meal [see Clinical Pharmacology (12.3)].
  * Advise patients to swallow ENVARSUS XR tablets whole with fluid (preferably water); patients must not chew, divide, crush or dissovle the tablets.
  * If a dose is missed, instruct the patient to take it as soon as possible within 15 hours after missing the dose. Beyond the 15-hour time frame, instruct the patient to wait until the usual scheduled time to take the next regular daily dose. Instruct the patient not to double the next dose.
  * Patients should avoid eating grapefruit or drinking grapefruit juice or alcoholic beverage while taking ENVARSUS XR [see Drug Interactions (7.2)].
This is a randomized, placebo-controlled, drug trial using sub-dissociative intranasal ketamine as an adjunct to standard pharmacotherapy for the management of pediatric sickle cell disease vasoocclusive pain crises in resource-poor settings. Pediatric patients will be enrolled at a teaching and referral hospital in West Africa. Patients will be randomly assigned to the treatment arm - standard therapy plus sub-dissociative intranasal ketamine (1 mg/kg) given at time zero) or the control arm - standard therapy plus intranasal normal saline (volume-matched to treatment arm), and patients will evaluated at standard intervals to assess for pain scores and vital signs (0 minutes, 30 minutes, 60 minutes, and 120 minutes). Pain will be assessed using the Faces Pain Scale - Revised (FPS-R). Patients will also be observed for any potential side effects or adverse events. All patients will be contacted 2-3 weeks post intranasal medication administration for over-the-phone follow-up using a portion of the PedsQL-SCD questionnaire, to assess for basic quality of life related to pain management and treatment.
The invention discloses an acne-removing traditional Chinese medicine composition which comprises the following traditional Chinese medicine raw materials in parts by weight: 110-130 parts of thunberg fritillary bulb, 75-85 parts of fructus forsythiae, 90-110 parts of trichosanthes root, 75-85 parts of calcined gypsum, 75-85 parts of raw sanguisorba, 75-85 parts of solanum lyratum, 85-95 parts of talc, 8-12 parts of alum, 75-85 parts of rhizoma bletillae and 85-95 parts of semen coicis. Also discloses an acne-removing traditional Chinese medicine preparation which is prepared by boiling, extracting and concentrating the acne-removing traditional Chinese medicine composition to obtain an extract and mixing the extract with yoghourt or tea water. The invention adopts Chinese herbal medicines to prepare the ointment, is externally applied to the affected part, and is safe to the human body without toxic and side effects. The synergistic effect of the medicines is utilized to achieve the effects of clearing away heat and toxic materials, removing acnes and freckles and regulating endocrine. Compared with traditional western medicines, the traditional Chinese medicine preparation has low price and greatly reduces the treatment cost of patients. Compared with the oral Chinese medicinal preparation, the preparation is safer and takes effect quickly.
The present invention relates to ventilating liquid for the lung cavity. The present invention is characterized in that the ventilating liquid is perfluorodecalin, the boiling temperature is from 140 to 142 DEG C, and the specific gravity is above 1.9. The ventilating liquid of the present invention is an essential tool for liquid ventilation, lung compliance can be obviously improved, airway pressure can be reduced, the oxygenation state of bodies can be improved, the degree of blood oxygen saturation is increased, and the damage of the lung tissue is suppressed. The present invention has a plurality of advantages which mechanical ventilation does not have. The present invention is a main method for the medical clinic treatment and salvage of acute respiratory distress syndrome in the future and is a main method for the resistance of 'SARS' and the adjuvant therapy and the salvage of 'acute respiratory distress syndrome' at present. The present invention can lower the death rate.
In addition to standard pharmacological treatment, this group would receive a diet comprising of 35-40kcal and 1.2-1.5gm protein per kg ideal body weight per day. The total distribution of the calories would be as 55-60% from carbohydrates, 20% from protein and 30-35% from fat, a fixed amount of 50g of ghee would be given in 3 divided doses of 30 ml to be taken raw, 20 ml to be used for cooking and the remaining amount of fat would be met by the invisible dietary fat. The source of visible fat would be exclusively Desi ghee. This group would not receive any fat in the form of butter or any other oil or any other nutritional supplement other than the prescribed diet. The diet would be explained to the patient by individual diet charts.
NEW MATERIAL:Monoclonal antibody 21-5-12 against human phenylalanine hydroxylase, secreted from hybridoma cell line 21-5-12. USE:A reagent useful for detection of human phenylalanine hydroxylase and other antigens capable of reacting with a monoclonal antibody by immune fluorescent microscopy, etc., for purification (isolation) and determination of the enzyme, especially for diagnosis, remedy, etc. of phenylketonuria. PREPARATION:Hybridoam cell line 21-5-12 is cultivated, and a yielded antibody is collected to obtain a monoclonal antibody 21-5-12 against human phenylalanine hydroxylase. The antibody is linked to a solid phase, a biological test specimen is added to it, the enzyme in the test specimen is linked to the antibody under heating. The linked material is washed, the enzyme is separated from the solid phase, and the enzyme is simply isolated from the test specimen. Further, the enzyme can be determined by using the isolated enzyme and the antibody labeled with radiation or an enzyme.
Participants rolling over from studies 202009 and 219288 who have stopped NA treatment during the parent study will be included in this arm. Participants will be followed up for 33 months. No study treatment will be administered in this study.
Because of its enhanced antitumor efficacy, lapatinib (LAP) is commonly used clinically in combination with the anthracycline drug doxorubicin (DOX) to treat metastatic breast cancer. While it is well recognized that this combination chemotherapy can lead to an increased risk of cardiotoxicity in adult women, its potential cardiotoxicity in the fetus during pregnancy remains understudied. Here, we aimed to examine the combination of LAP chemotherapy and DOX-induced cardiotoxicity in the fetus using a zebrafish embryonic system and investigate the underlying pathologic mechanisms. First, we examined the dose-dependent cardiotoxicity of combined LAP and DOX exposure in zebrafish embryos, which mostly manifested as pericardial edema, bradycardia, cardiac function decline and reduced survival. Second, we revealed that a significant increase in oxidative stress concurrent with activated MAPK signaling, as indicated by increased protein expression of phosphorylated p38 and Jnk, was a notable pathophysiological event after combined LAP and DOX exposure. Third, we showed that inhibiting MAPK signaling by pharmacological treatment with the p38MAPK inhibitor SB203580 or genetic ablation of the map2k6 gene could significantly alleviate combined LAP and DOX exposure-induced cardiotoxicity. Thus, we provided both pharmacologic and genetic evidence to suggest that inhibiting MAPK signaling could exert cardioprotective effects. These findings have implications for understanding the potential cardiotoxicity induced by LAP and DOX combinational chemotherapy in the fetus during pregnancy, which could be leveraged for the development of new therapeutic strategies.
The participant is assigned to receive a flyer that includes a message emphasizing the involvement of academic researchers and a $20 incentive. Then the participant is assigned to be a message that emphasizes the disproportionate impact of COVID-19 on certain ethnic and racial groups.
FIELD: medicine, oncology, immunology. SUBSTANCE: invention relates to immunostimulator inducing tumor-specific immune cellular response and to method for its preparing. Immunostimulator comprises tumor cells being at least part of them have on cellular surface as minimum one haplotype ГКГ-I of patient. Cells have been loaded with one or some peptides binding ГКГ-1 molecule and mentioned tumor cells are recognized as foreign cells in surrounding by peptides of the patient immune system and they induce immune cellular response. Loading is carried out in the presence of polycation, such as polylysine. The advantage of invention involves the enhancement of antitumor activity. EFFECT: improved preparing method, enhanced antitumor activity. 26 cl, 5 dwg, 5 ex
Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
Hypnosis is an effective treatment option for a variety of concerns. Past research has suggested that those who score in the high range of hypnotizability initially show greater improvement than those in the low range. A post hoc analysis was conducted to examine the extent to which hypnotizability modulates the reduction of hot flash frequency. Average number of hot flashes reported during hypnosis treatment and a 12-week follow-up were grouped according to participants' level of hypnotizability. Using baseline data, the reduction percentage of hot flash frequency was plotted and visually examined to determine when a clinically significant reduction (50%) in hot flashes was reached. Our results suggested that, regardless of hypnotizability, participants ultimately obtained a 50% reduction in hot flash frequency. Interestingly, participants who were rated as either moderately or highly hypnotizable achieved a 50% reduction by Week 3 while those of low hypnotizability did not cross the 50% reduction threshold until the 12-week follow-up. Implications from these findings include the importance of assessing hypnotizability in clinical settings to better tailor treatment dose and expectations.
Symptoms may result from an excess or deficit of one or more of the ions present in TPN Electrolytes. Therefore, frequent monitoring of electrolyte blood levels is recommended. Sodium excess can cause edema and exacerbation of congestive heart failure. Excess potassium can cause deviations from the normal ECG (electrocardiogram). Potassium deficits can impair neuromuscular function, causing muscle weakness or frank paralysis, intestinal dilatation and ileus. Calcium deficits can produce neuromuscular hyperexcitability, ranging from paresthesias, cramps and laryngospasm to tetany and grand mal seizures. Depressed calcium levels can accompany administration of parenteral phosphorous or large amounts of albumin. Magnesium deficiency can precipitate neuromuscular dysfunction, hyperirritability, psychotic behavior, tachycardia and hypertension. Magnesium excess can cause muscle weakness, ECG changes, sedation and mental confusion.